pharmaphorum Podcast

In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Simon Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialise long-standing research programmes from Gustav Roussy, Institut Curie, the University of Strasbourg, and Pierre Fabre, to develop drugs that overcome tumour resistance to existing drug treatments.

In today’s pharmaphorum podcast, brought to you by Lannett Corporation, editor in chief Jonah Comstock first chats with Timothy Crew, CEO of Lannett. Crew talks about the contract development manufacturing organisation (CDMO) business and why local manufacturing is important in the United States.
Then, in part 2, Jonah talks to Tom Lewis, Lannett’s VP of Global Supply Chain and CDMO Management. They discuss Lannett’s CDMO business more broadly, how it works, and why it’s an important offering in today’s pharma landscape.

Almost everyone seems to agree that drug prices are too high. But that agreement stops when it comes to the question of why they’re so high, and to the question of how to bring them down. 
Goodroot CEO Mike Waterbury and Nuwae Health CEO Ralph Pisano discuss how the community of Goodroot companies, including Nuwae, are attacking that issue from different angles. 

Angelini Ventures is a recently launched investment fund seeking companies that are transformational in healthcare. Founder of pharmaphorum and Healthware Group's chief content officer, Paul Tunnah, talks with Nils Bottler, who recently joined Angelini Ventures as Principal, about his career and where Angelini Ventures aims to have an impact.

For the newest pharmaphorum podcast, editor in chief Jonah Comstock welcomes Dr. Kristina Allikmets, SVP and head of R&D at Takeda’s plasma-derived therapies business unit. 

In this episode of the pharmaphorum podcast, host Jonah Comstock welcomes Marc de Garidel, CEO of CinCor Pharma, which was just recently sold to AstraZeneca for more than $1 billion USD. Marc tells Jonah all about CinCor and its unique approach to hypertension, how the AstraZeneca deal came about, and what happens next.

No matter what industry you’re in, artificial intelligence is a major topic around the water cooler. But while AI in popular culture may be at a peak of hype, AI in pharma is strending toward a moment of maturity, reliability, and scalability.
In today’s pharmaphorum podcast, brought to you by Syneos Health, Leigh Householder, EVP and MD technology and data solutions at Syneos Health and Noolie Gregory, VP decentralised clinical trial operations at Syneos Health, join host Jonah Comstock to talk about the Syneos Health 2023 Health Trends Report, particularly the opening section on AI: Finally Fit for Purpose.

At the beginning of February, pharmaphorum web editor Nicole Raleigh travelled to Rome to cover the inaugural VITA Accelerator demo day. After the event, VITA’s senior programme manager Anastasiya Markvarde and managing director Paolo Borella took time to discuss the ethos behind the accelerator and the future of digital health start-ups in Italy and beyond.

Angelini Ventures is a recently launched investment fund seeking companies that are transformational in healthcare. pharmaphorum founder and Healthware Chief Content Officer Paul Tunnah, talks with co-Managing Director Elia Stupka about the new €300 million fund, how it started, how it’s going, and what health innovation looks like from the investor’s perspective.
This podcast was produced in partnership with Angelini Ventures and was originally published on Matthew Holt’s Healthcare Blog Podcast.

 This time around on the pharmaphorum podcast, Editor in Chief Jonah Comstock chats with Nathan Buchbinder, cofounder and chief product officer at Proscia about pathology data, why it has taken so long to digitise it, and what the possibilities are when this data is freed from its historical siloes.